Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 2282512A

Drug Profile

GSK 2282512A

Alternative Names: FLU Q-QIV; FluLaval Quadrivalent; Flulaval Tetra; FLuZactal Tetra; GSK-2282512A; GSK-2833489A; Quadrivalent seasonal influenza vaccine - GlaxoSmithKline

Latest Information Update: 23 Nov 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline Biologicals
  • Class Antivirals; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 21 Nov 2016 Registered for Influenza virus infections (Prevention, In infants, In children) in USA (IM)
  • 02 Feb 2016 Registered for Influenza virus infections (Prevention, In infants, In children, In adolescents, In adults) in Mexico (IM) before February 2016
  • 02 Feb 2016 GlaxoSmithKline files sBLA for inclusion of infants and children aged 6 months to 35 months for Influenza virus infections (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top